Study ID,Study,Experiment Name,Experiment Notes,Strain Ont ID,Strain,Sex,Age,# of Animals,Sample Notes,Clinical Measurement Ont ID,Phenotype,Formula,Clinical Measurement Notes,Average Type,Value,Units,SEM,SD,Method Ont ID,Method,Method Site,Method Duration,Method Notes,Post Insult Type,Post Insult Time Value,Post Insult Time Unit,Conditions,Record ID,Condition 1a,Condition 1b,Condition 2a,Condition 2b 711,"Martin AM, et al., Diabetes 1999 Nov;48(11):2138-44",glucose metabolism trait,,RS:0000073,BBDR/Rhw,not specified,70 days to 0 days,12,,CMO:0001582,post-insult time to onset of diabetes mellitus,,,,11,d,1.0,3.4641,MMO:0000112,blood glucose analysis,,0.0,anti-RT6.1mAB and poly I:C,injection,,,anti-RT6.1 antibody (2 ml) (for 28 days) and Poly I:C (5 ug/g) (for 28 days),66148,anti-RT6.1 antibody (2 ml) (for 28 days),Poly I:C (5 ug/g) (for 28 days),, 711,"Martin AM, et al., Diabetes 1999 Nov;48(11):2138-44",glucose metabolism trait,,RS:0000073,BBDR/Rhw,not specified,70 days to 0 days,12,,CMO:0001136,percentage of study population developing type 1 diabetes mellitus during a period of time,,,,100,%,,,MMO:0000112,blood glucose analysis,,0.0,anti-RT6.1mAB and poly I:C,injection,,,anti-RT6.1 antibody (2 ml) (for 28 days) and Poly I:C (5 ug/g) (for 28 days),66147,anti-RT6.1 antibody (2 ml) (for 28 days),Poly I:C (5 ug/g) (for 28 days),, 690,"Fuller JM, et al., Physiol Genomics. 2009 Apr 7.",effector T cell quantity,,RS:0000073,BBDR/Rhw,not specified,30 days to 25 days,75,,CMO:0001121,blood CD4 cell to R73 cell ratio,,,median,75,%,,,MMO:0000310,fluorescence-activated cell sorting method,,0.0,,,,,specific pathogen-free conditions,67843,specific pathogen-free conditions,,, 690,"Fuller JM, et al., Physiol Genomics. 2009 Apr 7.",effector T cell quantity,,RS:0000073,BBDR/Rhw,not specified,30 days to 25 days,75,,CMO:0001120,blood R73 cell to total mononuclear cell ratio,,,median,60,%,,,MMO:0000310,fluorescence-activated cell sorting method,,0.0,,,,,specific pathogen-free conditions,67842,specific pathogen-free conditions,,, 690,"Fuller JM, et al., Physiol Genomics. 2009 Apr 7.",effector T cell quantity,,RS:0000073,BBDR/Rhw,not specified,30 days to 25 days,75,,CMO:0001122,blood CD8 cell count to R73 cell count ratio,,,median,22,%,,,MMO:0000310,fluorescence-activated cell sorting method,,0.0,,,,,specific pathogen-free conditions,67844,specific pathogen-free conditions,,, 1241,"Furuya T, et al., Hum Mol Genet 2000 Sep 22;9(15):2241-50",joint integrity trait,,RS:0000073,BBDR/Rhw,female,126 days to 66 days,13,,CMO:0001456,percentage of study population developing chronic experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (50 %) (between 1 and 7 days) and type II collagen (2 mg/kg) (between 1 and 7 days) then Freund's incomplete adjuvant (50 %) (between 1 and 35 days) and type II collagen (100 ug) (between 1 and 35 days),69922,Freund's incomplete adjuvant (50 %) (between 1 and 7 days),type II collagen (2 mg/kg) (between 1 and 7 days),Freund's incomplete adjuvant (50 %) (between 1 and 35 days),type II collagen (100 ug) (between 1 and 35 days) 1241,"Furuya T, et al., Hum Mol Genet 2000 Sep 22;9(15):2241-50",joint integrity trait,,RS:0000073,BBDR/Rhw,male,126 days to 66 days,11,,CMO:0001456,percentage of study population developing chronic experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (50 %) (between 1 and 7 days) and type II collagen (2 mg/kg) (between 1 and 7 days) then Freund's incomplete adjuvant (50 %) (between 1 and 35 days) and type II collagen (100 ug) (between 1 and 35 days),69921,Freund's incomplete adjuvant (50 %) (between 1 and 7 days),type II collagen (2 mg/kg) (between 1 and 7 days),Freund's incomplete adjuvant (50 %) (between 1 and 35 days),type II collagen (100 ug) (between 1 and 35 days) 1241,"Furuya T, et al., Hum Mol Genet 2000 Sep 22;9(15):2241-50",blood autoantibody amount,,RS:0000073,BBDR/Rhw,female,126 days to 66 days,13,,CMO:0001281,calculated serum anti-rat type 2 collagen autoantibody titer,,titer,,31.7,,1.7473,6.3,MMO:0000075,enzyme linked immunosorbent assay,,0.0,,,,,Freund's incomplete adjuvant (50 %) and type II collagen (2 mg/kg) ,69926,Freund's incomplete adjuvant (50 %) ,type II collagen (2 mg/kg) ,, 1241,"Furuya T, et al., Hum Mol Genet 2000 Sep 22;9(15):2241-50",blood autoantibody amount,,RS:0000073,BBDR/Rhw,male,126 days to 66 days,11,,CMO:0001281,calculated serum anti-rat type 2 collagen autoantibody titer,,titer,,30.6,,1.5076,5.0,MMO:0000075,enzyme linked immunosorbent assay,,0.0,,,,,Freund's incomplete adjuvant (50 %) and type II collagen (2 mg/kg) ,69925,Freund's incomplete adjuvant (50 %) ,type II collagen (2 mg/kg) ,, 690,"Fuller JM, et al., Physiol Genomics. 2009 Apr 7.",effector T cell quantity,,RS:0000073,BBDR/Rhw,not specified,30 days to 25 days,75,,CMO:0000598,blood CD4 cell count to CD8 cell count ratio,,,median,340,%,,,MMO:0000310,fluorescence-activated cell sorting method,,0.0,,,,,specific pathogen-free conditions,67846,specific pathogen-free conditions,,,